An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema

Trial Profile

An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs BCX 7353 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions
  • Acronyms APeX-S
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2018 New trial record
    • 28 Feb 2018 According to a media release, Henriette Farkas, MD, PhD, DSc is the Principal Investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top